BioSpace News Archive

Deals

Ginkgo Strengthens Cell and Gene Therapy Services with Circularis, Altar (Updated)

Ginkgo Bioworks opened its wallet Tuesday and snapped up Circularis and Altar to strengthen its cell and gene therapy programs and bolster its manufacturing capabilities.

October 4, 2022
·
3 min read
·
Alex Keown
Drug Development

Safety Concerns End KalVista Angioedema Trial

KalVista Pharmaceuticals announced Tuesday that life-threatening safety concerns prompted it to shut down a mid-stage clinical trial for hereditary angioedema.

October 4, 2022
·
2 min read
·
Paul Elias
Business

Sanofi, miRecule Ink Muscular Dystrophy Research Deal Worth up to $430M

miRecule inked Tuesday a research partnership and licensing deal with Sanofi worth $30 million that will advance a best-in-class antibody-RNA conjugate to treat FSHD.

October 4, 2022
·
3 min read
·
Mark Terry
Business

BMS Invests in Protein Degradation, Cell Therapy Platforms

Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.

October 4, 2022
·
3 min read
·
Mark Terry
Drug Development

Pfizer, Clovis Make Inroads Against Tough to Treat Prostate Cancer

Early data from the Phase III TALAPRO-2 study showed Talzenna, Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients.

October 4, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Araris Biotech AG Nabs $24M to Bring ADC, Linker Programs to Clinic

Araris Biotech AG secured $24 million in financing to advance the development of its proprietary antibody-drug conjugate (ADC)-linker technology and drive its own ADC candidates into the clinic.

October 4, 2022
·
3 min read
·
Alex Keown
Business

BlueSphere Bio’s Newly Minted CEO Calls for Urgency on Day One

With ambitions to enter the clinic in the first half of 2023, Keir Loiacono, esq., aims to double down on BlueSphere’s strengths rather than make any major course corrections.

October 4, 2022
·
4 min read
·
Gail Dutton
BioMidwest

Ampio Pharmaceuticals Issues Letter to Stockholders - October 04, 2022

Ampio Pharmaceuticals, Inc., released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino.

October 4, 2022
·
5 min read
Biotech Bay

Hundreds of Attendees Participate in ValConnect, ValGenesis’ Annual User Conference

ValGenesis Inc. successfully concluded its virtual annual user conference on Wednesday September 28th.

October 4, 2022
·
3 min read
Deals

TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies

TrialSpark announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.

October 4, 2022
·
2 min read